SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001140361-23-001688
Filing Date
2023-01-13
Accepted
2023-01-13 17:28:47
Documents
1
Group Members
BENJAMIN ROVINSKIDANIEL HETUGERALD BRUNKLUMIRA CAPITAL GP, L.P.LUMIRA CAPITAL II (INTERNATIONAL), L.P.LUMIRA CAPITAL II, L.P.LUMIRA GP HOLDINGS CO.LUMIRA GP INC.PETER VAN DER VELDENVASCO LARCINA

Document Format Files

Seq Description Document Type Size
1 SC 13D/A brhc10046676_sc13da.htm SC 13D/A 397575
  Complete submission text file 0001140361-23-001688.txt   399535
Mailing Address 100 SPY COURT MARKHAM A6 L3R 5H6
Business Address 100 SPY COURT MARKHAM A6 L3R 5H6 (905) 475-1234
Edesa Biotech, Inc. (Subject) CIK: 0001540159 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-87615 | Film No.: 23529722
SIC: 2834 Pharmaceutical Preparations

Mailing Address 141 ADELAIDE STREET WEST SUITE 770 TORONTO A6 M5H 3L5
Business Address 141 ADELAIDE STREET WEST SUITE 770 TORONTO A6 M5H 3L5 416-213-4223
Lumira Capital Investment Management Inc. (Filed by) CIK: 0001702636 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: SC 13D/A